최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Headache, v.59 no.7, 2019년, pp.1052 - 1062
Tepper, Stewart J. (Geisel School of Medicine at Dartmouth, Hanover, NH, USA) , Krege, John H. (Eli Lilly and Company, Indianapolis, IN, USA) , Lombard, Louise (Eli Lilly and Company, Indianapolis, IN, USA) , Asafu‐Adjei, Josephine K. (Eli Lilly and Company, Indianapolis, IN, USA) , Dowsett, Sherie A. (Eli Lilly and Company, Indianapolis, IN, USA) , Raskin, Joel (Eli Lilly and Company, Indianapolis, IN, USA) , Buchanan, Andrew S. (Eli Lilly and Company, Indianapolis, IN, USA) , Friedman, Deborah I. (University of Texas, Southwestern Medical Center, Dallas, TX, USA)
Trial DesignSAMURAI and SPARTAN were double‐blind, placebo‐controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only). Individuals with migraine were randomized to receive oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or pl...
Vila-Pueyo, Marta. Targeted 5-HT 1F Therapies for Migraine. Neurotherapeutics, vol.15, no.2, 291-303.
Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain : a journal of neurology, vol.142, no.7, 1894-1904.
Kuca, Bernice, Silberstein, Stephen D., Wietecha, Linda, Berg, Paul H., Dozier, Gregory, Lipton, Richard B.. Lasmiditan is an effective acute treatment for migraine : A phase 3 randomized study. Neurology, vol.91, no.24, e2222-e2232.
Goldstein, DJ, Roon, KI, Offen, WW, Ramadan, NM, Phebus, LA, Johnson, KW, Schaus, JM, Ferrari, MD. Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. The Lancet, vol.358, no.9289, 1230-1234.
Gallagher, R. Michael, Kunkel, Robert. Migraine Medication Attributes Important for Patient Compliance: Concerns About Side Effects May Delay Treatment. Headache, vol.43, no.1, 36-43.
Dodick, DW, Martin, V. Triptans and CNS Side-Effects : pharmacokinetic and metabolic mechanisms. Cephalalgia : an international journal of headache, vol.24, no.6, 417-424.
Stewart, W.F., Lipton, R.B., Whyte, J., Dowson, A., Kolodner, K., Liberman, J.N., Sawyer, J.. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology, vol.53, no.5, 988-988.
Stewart, WF, Lipton, RB, Kolodner, K, Liberman, J, Sawyer, J. Reliability of the Migraine Disability Assessment Score in A Population-Based Sample of Headache Sufferers. Cephalalgia : an international journal of headache, vol.19, no.2, 107-114.
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., Stewart, W. F.. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, vol.68, no.5, 343-349.
Cady, Roger K., Martin, Vincent T., Géraud, Gilles, Rodgers, Anthony, Zhang, Ying, Ho, Andrew P., Hustad, Carolyn M., Ho, Tony W., Connor, Kathryn M., Ramsey, Karen E.. Rizatriptan 10-mg ODT for Early Treatment of Migraine and Impact of Migraine Education on Treatment Response. Headache, vol.49, no.5, 687-696.
Dodick, David, Brandes, Jan, Elkind, Arthur, Mathew, Ninan, Rodichok, Lawrence. Speed of Onset, Efficacy and Tolerability of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine : A Randomised, Double-Blind, Placebo-Controlled Study. Cns drugs, vol.19, no.2, 125-136.
Cady, Roger K, McAllister, Peter J, Spierings, Egilius LH, Messina, John, Carothers, Jennifer, Djupesland, Per G, Mahmoud, Ramy A. A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study). Headache, vol.55, no.1, 88-100.
Ho, T.W., Ferrari, M.D., Dodick, D.W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., Koppen, H., Winner, P.K.. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. The Lancet, vol.372, no.9656, 2115-2123.
MedGenMed Landy S 53 9 2007 Two double‐blind, multicenter, randomized, placebo‐controlled, single‐dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: Function, productivity, and satisfaction outcomes
ECDEU Assessment Manual for Psychopharmacology‐Revised Guy W 218 1976
Efron, Bradley. Better Bootstrap Confidence Intervals. Journal of the American Statistical Association, vol.82, no.397, 171-185.
Cephalalgia Pilgrim A 24 29 2009 Col‐144, an orally bioavailable selective 5‐HT1F receptor agonist for acute migraine therapy: Po34
Imitrex.GlaxoSmithKline;2017. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020132s029lbl.pdf. Accessed February 8 2019.
Maxalt.MSD Ltd;2011. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020864s011s016s017s018s019 020865s012s016s018s020s021lbl.pdf. Accessed February 8 2019.
Amerge.GlaxoSmithKline;2016. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020763s011lbl.pdf. Accessed February 8 2019.
Relpax.Pfizer;2013. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021016s021s023s024s027lbl.pdf. Accessed February 8 2019.
Zomig.AstraZeneca;2018. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020768s023 021231s014 021450s010lbl.pdf. Accessed February 8 2019.
An Open‐label Long‐term Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR). ClinicalTrials.gov Registration Number NCT02565186.ClinicalTrials.gov;2015.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.